文献速递肝病

非酒精性脂肪性肝病患者接种新冠疫苗的安全性与免疫原性:多中心研究

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
PubMed 文献 · J Hepatol · 2021-04-24

该多中心研究纳入381例无SARS-CoV-2感染史的非酒精性脂肪性肝病(NAFLD)患者,接种2剂灭活新冠疫苗。结果显示7天内不良反应发生率为24.9%,28天为29.4%,均为轻度自限性,无3级不良反应;全程接种后至少14天,95.5%患者检出中和抗体,中位滴度为32,且滴度维持。结论认为灭活疫苗在NAFLD患者中安全且免疫原性良好。

要点

  • NAFLD患者接种2剂灭活新冠疫苗后不良反应均为轻度自限性,无3级不良反应。
  • 全程接种后95.5%的NAFLD患者产生中和抗体,中位滴度32且维持。
  • 灭活新冠疫苗在NAFLD患者中显示出良好的安全性及免疫原性。

核心结论

  • 灭活新冠疫苗在NAFLD患者中安全且具有良好免疫原性。

研究设计与样本

  • 多中心研究,纳入中国11个中心381例无SARS-CoV-2感染史的NAFLD患者,接种2剂灭活新冠疫苗。

主要发现

  • 每剂接种后7天内不良反应发生率为24.9%(95例),28天内总不良反应发生率为29.4%(112例)。
  • 最常见不良反应为注射部位疼痛70例(18.4%),其次为肌肉疼痛21例(5.5%)和头痛20例(5.2%)。
  • 所有不良反应均为轻度自限性,未记录到3级不良反应。
  • 全程接种后至少14天,364例(95.5%)患者检出SARS-CoV-2中和抗体,中位滴度为32(IQR 8-64),且滴度维持。

临床怎么用

  • NAFLD患者可考虑接种灭活新冠疫苗,安全性良好且能产生中和抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in NAFLD. METHODS: This multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection. All patients were vaccinated with 2 doses of inactivated vaccine against SARS-CoV-2. The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination. RESULTS: A total of 381 patients with pre-existing NAFLD were included from 11 designated centers in China. The median age was 39.0 years (IQR 33.0-48.0 years) and 179 (47.0%) were male. The median BMI was 26.1 kg/m2 (IQR 23.8-28.1 kg/m2). The number of adverse reactions within 7 days after each injection and adverse reactions within 28 days totaled 95 (24.9%) and 112 (29.4%), respectively. The most common adverse reactions were injection site pain in 70 (18.4%), followed by muscle pain in 21 (5.5%), and headache in 20 (5.2%). All adverse reactions were mild and self-limiting, and no grade 3 adverse reactions were recorded. Notably, neutralizing antibodies against SARS-CoV-2 were detected in 364 (95.5%) patients with NAFLD. The median neutralizing antibody titer was 32 (IQR 8-64), and the neutralizing antibody titers were maintained. CONCLUSIONS: The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD. LAY SUMMARY: The development of vaccines against coronavirus disease 2019 (COVID-19) has progressed rapidly, with encouraging safety and efficacy data. This study now shows that the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in the large population of patients with non-alcoholic fatty liver disease.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol. 2021. PMID: 33905793. doi:10.1016/j.jhep.2021.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。